(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 20.71% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 134.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Evolus's revenue in 2025 is $285,823,000.On average, 9 Wall Street analysts forecast EOLS's revenue for 2025 to be $19,570,389,185, with the lowest EOLS revenue forecast at $18,714,119,839, and the highest EOLS revenue forecast at $20,268,498,259. On average, 9 Wall Street analysts forecast EOLS's revenue for 2026 to be $24,825,329,074, with the lowest EOLS revenue forecast at $23,471,891,984, and the highest EOLS revenue forecast at $26,264,976,477.
In 2027, EOLS is forecast to generate $32,584,257,219 in revenue, with the lowest revenue forecast at $29,874,790,248 and the highest revenue forecast at $36,013,223,793.